HRAS Protein (Transcript Variant 3) (Myc-DYKDDDDK Tag)
-
- Target See all HRAS Proteins
- HRAS (HRas proto-oncogene, GTPase (HRAS))
- Protein Type
- Recombinant
- Protein Characteristics
- Transcript Variant 3
-
Origin
- Human
-
Source
- HEK-293 Cells
- Purification tag / Conjugate
- This HRAS protein is labelled with Myc-DYKDDDDK Tag.
- Application
- Antibody Production (AbP), Standard (STD)
- Characteristics
-
- Recombinant human HRAS (transcript variant 3) protein expressed in HEK293 cells.
- Produced with end-sequenced ORF clone
- Purity
- > 80 % as determined by SDS-PAGE and Coomassie blue staining
- Top Product
- Discover our top product HRAS Protein
-
Want other Options for this Protein ?
!Discover Our Predefined Custom Proteins and Custom Protein Services!Your project requires further customization? Contact us and discover our custom protein solutions
-
-
- Application Notes
-
Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays - Comment
-
The tag is located at the C-terminal.
- Restrictions
- For Research Use only
-
- Concentration
- 50 μg/mL
- Buffer
- 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.
- Storage
- -80 °C
- Storage Comment
- Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.
-
- Target
- HRAS (HRas proto-oncogene, GTPase (HRAS))
- Alternative Name
- Hras (HRAS Products)
- Background
- This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene.
- Molecular Weight
- 21.1 kDa
- NCBI Accession
- NP_001123914
- Pathways
- p53 Signaling, MAPK Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Hepatitis C, Autophagy, Signaling Events mediated by VEGFR1 and VEGFR2, Signaling of Hepatocyte Growth Factor Receptor, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling, BCR Signaling
-